Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.
Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.
Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.
If left untreated, TTTS can have devastating consequences. Medical research indicates that:
TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.
Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.
Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.
Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:
Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.
Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.
Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.
According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.
When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.
Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.
Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."
Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.
Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.
The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.
Credits: Public Domain
Wegovy: The maker of the well-known weight-loss and diabetes drugs Wegovy and Ozempic has lowered the prices for most of its products. Novo Nordisk announced that the monthly cost for injectable Wegovy and Ozempic will now be reduced for people who buy the medicines directly from the company, through telehealth partners or at retail pharmacies. The only dose not included in the cut is the 2 mg version of Ozempic, which will stay at 499 dollars per month.
This move is expected to reshape how much patients spend on these popular weight-loss and diabetes medicines. Here is what the change means for regular users.
The company’s decision comes after pressure from the Trump administration, which urged Novo Nordisk and rival Eli Lilly to reduce prices on popular weight-loss and diabetes treatments. Earlier in November, President Donald Trump announced that Medicare would begin covering Novo’s Wegovy and Lilly’s Zepbound for millions of older adults. Both companies also agreed to sell discounted versions of the medications through a new federal direct-to-consumer platform called TrumpRx, expected to launch in 2026.
Novo Nordisk continues to face challenges from compounding pharmacies that sell cheaper, non-approved copies of semaglutide, the active ingredient used in Wegovy and Ozempic.
“As pioneers of the GLP-1 class, we are committed to ensuring that real, FDA-approved Wegovy and Ozempic are affordable and accessible to those who need them,” said Dave Moore, executive vice president at Novo Nordisk. He added that the American healthcare system includes different types of coverage and purchasing options, and the updated savings programs aim to give faster financial relief to people without insurance or those choosing to pay on their own, as reported by USA Today.
Novo Nordisk has introduced new, lower prices for most doses of its leading weight-loss and diabetes medicines, Wegovy and Ozempic. The standard monthly rate for these medications is now set at 349 dollars for customers purchasing through the drugmaker, telehealth services or retail pharmacies. For first-time users, the .25 mg and .5 mg doses are priced at 199 dollars per month during the first two months. This introductory offer remains available until March 31, 2026, according to USA Today.
Many people have found GLP-1 medications difficult to afford because they carry steep price tags and are not widely covered by insurance. Wegovy’s current list price is $1,349.
Coverage has grown, but only gradually. A Mercer survey showed that in 2024, 44 percent of large employers offered coverage for GLP-1 drugs for weight management, compared with 41 percent the year before. Insurers tend to approve these medicines more readily when they are prescribed for diabetes or health issues such as heart conditions or sleep apnea.
Both companies are also working on tablet forms of their injectable weight-loss drugs. Earlier this month, Trump said that the upcoming oral versions would be offered at $149 per month once they reach the market.
According to Moore, Novo expects the FDA to clear the Wegovy pill by late 2025, with availability planned for early 2026. Lilly has applied for priority review of its own oral drug, orforglipron. Novo is also awaiting the FDA’s priority review for a higher-dose injectable form of Wegovy.
Credits: Canva
With the aim of preventing and detecting cervical cancer among women in Kerala, Health Minister Veena George shared that the health department's campaign, ‘Aarogyam Anandam Akratham Arbutham,’ has seen participation from over 20 lakh people. Out of these, around 30,000 individuals underwent further examination, and cancer was confirmed in 84 of them. Additionally, 243 individuals showed pre-cancerous signs. By identifying and treating these early warning signs, the minister emphasized that cervical cancer can often be prevented.
Cervical cancer remains one of the major cancers affecting women, she noted. While multiple factors can contribute to its development, the primary cause is infection with the human papillomavirus (HPV). Research indicates that roughly 7.9% of women in Kerala are affected by cervical cancer. Early detection is key, as it allows treatment to proceed without serious complications. Screening facilities are available to help in early identification.
Cervical cancer develops in the cervix, the lower portion of the uterus. It is almost always linked to a long-lasting HPV infection, which can cause normal cells to change and grow uncontrollably. While the body often clears HPV naturally, persistent infection can lead to pre-cancerous cell changes. If these changes are left untreated, they may progress into invasive cancer.
Some common warning signs of cervical cancer include abnormal vaginal bleeding (between periods, after sexual intercourse, or post-menopause), unusual vaginal discharge (which may be watery, bloody, or foul-smelling), and pelvic pain. As the cancer advances, more severe symptoms such as swelling in the legs, ongoing fatigue, and problems with urination or bowel movements can develop, according to the National Cancer Institute.
Catching cervical cancer early is critical because it allows treatment to begin before the disease advances, significantly improving survival chances. Cervical cancer usually develops slowly and may not cause symptoms in the early stages, making regular screening vital.
Most cases of cervical cancer are caused by HPV, a sexually transmitted infection. HPV spreads through sexual contact—including vaginal, anal, or oral sex—and can lead to cancer. Many people contract HPV at some point without realizing it, as their immune system may fight it off naturally. However, if the infection persists, it can trigger changes in cervical cells that may become cancerous.
Early detection relies on routine screening tests such as the Pap test (Pap smear) and the HPV test, which can detect precancerous changes or high-risk HPV infections before cancer develops. If screening results are abnormal, a colposcopy with a biopsy may be conducted for a closer examination of the cervix.
The HPV vaccine protects against genital warts and the majority of cervical cancer cases. It also shields against cancers of the vagina, vulva, penis, or anus caused by HPV, as well as cancers of the mouth, throat, and head and neck linked to the virus.
The vaccine works by helping the body develop immunity to certain HPV strains, making it easier to fight off infection if exposed later.
India is expanding HPV vaccination to prevent cervical cancer, targeting girls aged 9–14 through school-based campaigns and incorporating the indigenously developed Cervavac into the National Immunization Program. The ideal age to start vaccination is 9–12 years, before sexual activity begins, though catch-up doses are allowed up to age 26. Some guidance even permits vaccination up to age 45. The government is preparing for a nationwide rollout, but final plans and vaccine supply are still being finalized.
Credits: Canva
Scientists and clinicians are cautioning the public not to mix two widely used over-the-counter medicines, warning that pairing them can put unnecessary strain on the body. Their appeal comes shortly after Donald Trump and Robert F Kennedy Jr made headlines with remarks about Tylenol and autism, a claim that experts have repeatedly dismissed.
The current concern is different. Physicians are asking people to avoid taking Tylenol and NyQuil together, even though they are sold for separate purposes. Tylenol is meant for general pain and fever, while NyQuil is marketed to ease cold and flu symptoms at night. Both contain acetaminophen, which means the doses can add up more quickly than people realize.
Dr Brynna Connor told Parade that many adults unintentionally take far more than the recommended daily amount. She explained that four thousand milligrams is the absolute upper limit for healthy adults, but she encourages most patients to stay well below three thousand. Going beyond that threshold, even briefly, can damage the liver. According to her, people often double up on acetaminophen without recognizing how fast it can lead to liver failure.
As per Healthline, the body can process acetaminophen safely, but only within a defined range. Exceeding it places stress on the liver, especially when multiple medications contain the same ingredient.
Dr Parth Bhavsar added that combining NyQuil with Benadryl can also lead to trouble. Both products include diphenhydramine, which may cause heavy drowsiness, slower breathing, confusion, dizziness, or difficulty urinating when taken together. He noted that these combinations can increase the risk of falls or memory lapses.
The advisories come months after Donald Trump and Robert F Kennedy Jr held a joint media briefing in which they suggested that Tylenol use during pregnancy might raise the likelihood of autism in newborns. Their statements drew widespread criticism from experts.
During the briefing, Trump struggled to pronounce “acetaminophen” and claimed the drug posed a “very increased risk of autism,” a statement that has not been supported by scientific research. A new analysis by researchers in the United Kingdom, Spain, and Australia reviewed nine major summaries of existing studies, including work Trump had referenced. Their conclusion was that there is no clear evidence linking paracetamol use in pregnancy to autism or ADHD.
The group also pointed out that many reviews had gaps in their methods or did not fully adjust for genetic and environmental factors. When those variables were accounted for, the suggested connection between Tylenol and autism weakened or disappeared.
Acetaminophen, known in many places as paracetamol and sold under names such as Tylenol and Panadol, is a common non-prescription medicine used to reduce fever and ease mild to moderate pain. It works as an analgesic and a fever reducer. It is different from drugs like ibuprofen because it does not address inflammation. As per the Food and Drug Administration.
The American College of Obstetricians and Gynecologists responded to the findings, saying the results were consistent with what the organization has long maintained. According to a spokesperson, available research does not show a causal link between responsible acetaminophen use in pregnancy and autism or other developmental conditions. In other words, the organization does not see enough evidence to support claims made by Trump or Kennedy.
© 2024 Bennett, Coleman & Company Limited